ArticleScientific reports2025
A QSPR study of coronary artery disease drugs using eccentricity-based indices.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative structure-property relationship (QSPR) and Quantitative structure-activity relationship QSAR modeling are constructed on the principle, which describes that biological activity and physicochemical properties of a chemical compound can be deduced from its chemical structure. These relationships are commonly developed from graph invariants that can be computed from the molecular graphs of chemical compounds. Coronary artery disease occurs when the coronary arteries become narrowed or blocked, which can restrict the flow of oxygen-rich blood to the heart. Coronary artery disease is the leading cause of disability-adjusted life years lost and death worldwide. This study advances QSPR modeling by using eccentricity-based graphical invariants, specifically designed to enhance the predictive accuracy for physicochemical properties of drugs used to treat coronary artery disease, including atorvastatin, simvastatin, rosuvastatin, aspirin, clopidogrel, metoprolol, atenolol, enalapril, lisinopril, amlodipine, diltiazem, nitroglycerin, isosorbide dinitrate, ranolazine, gemfibrozil, and fenofibrate. We used the cubic, logarithmic, quadratic, and linear models to explore the structure-property relationship of drugs for coronary artery disease. We designed the models on the basis of the adjusted r-squared values, assuming the eccentricity-based invariants as independent variables, while the physico-chemical properties of sixteen drugs as dependent variables. The dependent variables include boiling point, enthalpy of vaporization, heavy atom count, molar volume, polarizability, complexity, molecular weight, and molar refractivity. The statistical analysis indicates that the most suitable structure-property models are nonlinear. The findings show that the eccentric Albertson index and the eccentric geometric arithmetic index attain superior predictive performance compared to other indices. The analysis shows that cubic regression is the optimal choice for predicting enthalpy of vaporization, molar refractivity, polarizability, and complexity. In contrast, quadratic regression is the best option for predicting molecular weight, while a linear model is most effective for assessing heavy atom count. Additionally, logarithmic regression is the most suitable choice for boiling point and molar volume. To validate the robustness of our regression models, we used them to assess the properties of five additional coronary artery disease drugs that were not part of the original dataset. The experimental values were compared with forecasted data, revealing a strong correlation between them. This demonstrates the reliability of our regression models in assessing these vital physicochemical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.